Patents Assigned to lonis Pharmaceuticals, Inc.
  • Modified compounds and uses thereof
    Patent number: 11332733
    Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: May 17, 2022
    Assignee: lonis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
  • Oligomer-conjugate complexes and their use
    Patent number: 11104899
    Abstract: Oligonucleotides, chemically-modified oligonucleotides, and oligonucleotide-conjugate complexes for use in research, diagnostics, and/or therapeutics are described herein. In some embodiments, oligonucleotides comprising a stabilized phosphate moiety covalently attached to the 5?-terminal nucleoside are provided.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: August 31, 2021
    Assignee: lonis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Eric E. Swayze, Walter F. Lima, Garth A. Kinberger
  • Modulation of prekallikrein (PKK) expression
    Patent number: 11053500
    Abstract: Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate PKK-associated diseases, disorders, and conditions.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: July 6, 2021
    Assignee: lonis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Huynh-Hoa Bui
  • Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression
    Patent number: 10954519
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: March 23, 2021
    Assignee: lonis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Susan M. Freier
  • Modulation of androgen receptor expression
    Patent number: RE48461
    Abstract: Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: March 9, 2021
    Assignee: lonis Pharmaceuticals, Inc.
    Inventors: Robert A. Macleod, Youngsoo Kim, Tianyuan Zhou, Susan M. Freier, Punit Seth, Eric Swayze, Brett Monia